All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75]
0.42 [0.01 ; 12.75 ] PRINCIPLE (COLCHICINE), 2021 1 0% 289 NA not evaluable deathsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61]
PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71]
PRINCIPLE, 2021 1.65 [0.03; 83.12]
PRINCIPLE (COLCHICINE), 2021 0.42 [0.01; 12.75]
Thomas (vitamin c only), 2021 2.11 [0.07; 64.28]
Thomas (vitamin c plus zinc), 2021 3.54 [0.16; 80.27]
1.38 [0.32 ; 5.98 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, PATCH Cohort 1 (Amaravadi), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021 6 0% 2,139 moderate not evaluable hospitalization or deathdetailed results Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92]
PRINCIPLE, 2021 0.81 [0.58; 1.13]
PRINCIPLE (COLCHICINE), 2021 1.29 [0.36; 4.67]
0.85 [0.63 ; 1.14 ] Hinks (ATOMIC2), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021 3 0% 2,241 moderate not evaluable A EFFACER PCR-negative (end of follow-up)detailed results Hinks (ATOMIC2), 2021 0.91 [0.57; 1.46]
0.91 [0.57 ; 1.46 ] Hinks (ATOMIC2), 2021 1 0% 295 NA not evaluable clinical deteriorationdetailed results PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68]
0.51 [0.07 ; 3.68 ] PATCH Cohort 1 (Amaravadi), 2021 1 0% 28 NA not evaluable clinical improvementdetailed results PRINCIPLE, 2021 1.08 [0.95; 1.23]
PRINCIPLE, 2021 1.21 [1.08; 1.36]
Thomas (vitamin c only), 2021 3.14 [0.60; 16.38]
Thomas (vitamin c plus zinc), 2021 0.85 [0.27; 2.65]
1.15 [1.04 ; 1.27 ] PRINCIPLE, 2021, PRINCIPLE, 2021, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021 4 9% 3,308 moderate not evaluable clinical improvement (7-day)detailed results Thomas (vitamin c only), 2021 3.14 [0.60; 16.38]
3.14 [0.60 ; 16.38 ] Thomas (vitamin c only), 2021 1 0% 98 NA not evaluable clinical improvement (time to event analysis only)detailed results PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.08 [0.95 ; 1.23 ] PRINCIPLE, 2021 1 0% 1,323 NA not evaluable hospitalizationdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76]
Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96]
PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93]
PRINCIPLE, 2021 0.94 [0.50; 1.75]
PRINCIPLE (COLCHICINE), 2021 1.73 [0.43; 7.07]
Roozbeh, 2020 0.23 [0.02; 2.21]
Thomas (vitamin c only), 2021 0.68 [0.11; 4.27]
Thomas (vitamin c plus zinc), 2021 2.15 [0.53; 8.80]
0.95 [0.66 ; 1.38 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Hinks (ATOMIC2), 2021, PATCH Cohort 1 (Amaravadi), 2021, PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021, Roozbeh, 2020, Thomas (vitamin c only), 2021, Thomas (vitamin c plus zinc), 2021 8 0% 2,490 moderate not evaluable mechanical ventilationdetailed results PRINCIPLE, 2021 0.50 [0.10; 2.60]
PRINCIPLE, 2021 1.02 [0.45; 2.33]
0.88 [0.42 ; 1.85 ] PRINCIPLE, 2021, PRINCIPLE, 2021 2 0% 2,624 moderate not evaluable ICU admissiondetailed results PRINCIPLE, 2021 0.76 [0.18; 3.18]
PRINCIPLE, 2021 0.54 [0.24; 1.21]
0.59 [0.29 ; 1.18 ] PRINCIPLE, 2021, PRINCIPLE, 2021 2 0% 2,611 moderate not evaluable recoverydetailed results PRINCIPLE, 2021 1.21 [1.08; 1.36]
PRINCIPLE (COLCHICINE), 2021 0.92 [0.72; 1.17]
1.08 [0.83 ; 1.40 ] PRINCIPLE, 2021, PRINCIPLE (COLCHICINE), 2021 2 75% 4,072 moderate not evaluable adverse eventsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85]
178.20 [73.71 ; 430.85 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1 0% 353 NA not evaluable 0.2 500.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-25 15:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 97
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290